May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Decreased Retreatments and Maintained Efficacy With Triple Therapy (Combination Verteporfrin Photodynamic Therapy, Intravitreal Avastin/Lucentis and Intravitreal Dexamethasone Treatments) for Patients With Exudative Age Related Macular Degeneration
Author Affiliations & Notes
  • M. J. Tolentino
    Ctr for Retina And Macular Disease, Winter Haven, Florida
  • A. Berger
    Ctr for Retina And Macular Disease, Winter Haven, Florida
  • D. Misch
    Ctr for Retina And Macular Disease, Winter Haven, Florida
  • S. Moon
    Ctr for Retina And Macular Disease, Winter Haven, Florida
  • R. Hamilton
    Ctr for Retina And Macular Disease, Winter Haven, Florida
  • M. J. Espiritu
    Ctr for Retina And Macular Disease, Winter Haven, Florida
  • Footnotes
    Commercial Relationships  M.J. Tolentino, Genetech,Pfizer, Eyetech,Novartis, C; Opko, P; QLT, Eyetech, Pfizer, Novartis, R; A. Berger, Qlt, Novartis, R; D. Misch, QLT, Novartis, R; S. Moon, None; R. Hamilton, Novartis, QLT, R; M.J. Espiritu, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 542. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. J. Tolentino, A. Berger, D. Misch, S. Moon, R. Hamilton, M. J. Espiritu; Decreased Retreatments and Maintained Efficacy With Triple Therapy (Combination Verteporfrin Photodynamic Therapy, Intravitreal Avastin/Lucentis and Intravitreal Dexamethasone Treatments) for Patients With Exudative Age Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):542.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine if triple therapy (combining intravitreal Avastin/Lucentis with PDT and intravitreal dexamethasone) can reduce the number of retreatments while maintaining improvement in vision in patients with exudative age related macular degeneration.

Methods: : : Previously treated or patients naïve to treatment with exudative age related macular degeneration treated with triple therapy (intravitreal injections of Avastin (1.25 mg)or Lucentis (0.5 mg), Verteporfrin photodynamic therapy and intravitreal injections of dexamethasone (800 ug)) were identified from the computerized records of one retina only private practices. The three therapies had to be performed within 2 weeks of each other. Reduced fluence (25J/M2) or standard fluence (50J/MM) PDT was allowed. Only patients with at least 3 month follow up were analyzed. Change in snellen visual acuity was the primary endpoint and the rate of retreatments was the secondary endpoints.

Results: : 78 eyes from 75 patients had at least 3 month follow-up and 57 eyes of 54 patients had at least 6 month follow-up. Patients with 3 month follow-up showed 16/78(21%) eyes gained more than 3 lines of vision, 69/78 (88%) eyes did not lose any lines of vision and 75/78 (96%) of eyes did not lose more than 3 lines of vision. Within the 3 month follow-up 56/78 (72%) did not need retreatment. Patients with 6 month follow-up showed 12/57 (21%) eyes gained more than 3 lines of vision, 49/57 (86%) eyes did not lose any lines of vision and 55/57(96%) of eyes did not lose more than 3 lines of vision. Within the 6 month follow-up only 34/57 (61%) did not need retreatment.

Conclusions: : Triple therapy appears to provide excellent efficacy and decreases the rate of retreatment.

Keywords: age-related macular degeneration • photodynamic therapy • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×